VYNE Therapeutics (VYNE) Other Non-Current Assets (2016 - 2025)
VYNE Therapeutics (VYNE) posted Other Non-Current Assets of $60000.0 for Q4 2025, down 75.1% on a QoQ basis from $241000.0 in Q2 2025, and down 97.35% year-over-year from $2.3 million in Q4 2024.
VYNE Therapeutics (VYNE) Other Non-Current Assets (2016 - 2025) Analysis & Trends
VYNE Therapeutics' Other Non-Current Assets history runs 9 years deep, the most recent figure standing at $60000.0 for Q4 2025.
- Quarterly Other Non-Current Assets fell 97.35% year-over-year to $60000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $60000.0 (down 97.35% YoY) and the FY2025 annual result came in at $60000.0, down 97.35% from the prior year.
- Other Non-Current Assets was $60000.0 for Q4 2025 at VYNE Therapeutics, down from $241000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $4.1 million in Q1 2021 and bottomed at $60000.0 in Q4 2025.
- A 5-year average of $2.1 million and a median of $2.3 million in 2024 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2023 — Other Non-Current Assets jumped 1415.0% — and 2025, when it slumped 97.35%.
- VYNE Therapeutics' Other Non-Current Assets stood at $3.5 million in 2021, then sank by 97.15% to $100000.0 in 2022, then soared by 1415.0% to $1.5 million in 2023, then soared by 49.31% to $2.3 million in 2024, then slumped by 97.35% to $60000.0 in 2025.
- Business Quant data shows VYNE's Other Non-Current Assets at $60000.0 in Q4 2025, $241000.0 in Q2 2025, and $1.3 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 1.02 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 60,000.00 |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 104.24 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.26 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 2.13 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 124.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 14.48 Mn |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 60,000.00 |
| Jun 30, 2025 | 241,000.00 |
| Mar 31, 2025 | 1.34 Mn |
| Dec 31, 2024 | 2.26 Mn |
| Sep 30, 2024 | 2.54 Mn |
| Jun 30, 2024 | 2.72 Mn |
| Mar 31, 2024 | 1.27 Mn |
| Dec 31, 2023 | 1.52 Mn |
| Sep 30, 2023 | 1.76 Mn |
| Jun 30, 2023 | 2.00 Mn |
| Mar 31, 2023 | 100,000.00 |
| Dec 31, 2022 | 100,000.00 |
| Sep 30, 2022 | 2.74 Mn |
| Jun 30, 2022 | 2.97 Mn |
| Mar 31, 2022 | 3.36 Mn |
| Dec 31, 2021 | 3.51 Mn |
| Sep 30, 2021 | 3.68 Mn |
| Jun 30, 2021 | 3.83 Mn |
| Mar 31, 2021 | 4.12 Mn |
| Dec 31, 2020 | 4.35 Mn |